announcements & circulars-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

investors

information disclosure

listing documents

financial reports

announcements & circulars

company presentation

corporate governance

stock information

ir contacts

email subscription

announcements & circulars

the announcement begins in december 2019

voluntary announcement - appointment of chief commercial officer 2021-11-02
voluntary announcement - first patient dosed in a phase ii/iii clinical trial of kn046 in combination with lenvatinib for the treatment of pd-(l)1 refractory advanced nsclc 2021-10-28
grant of share options 2021-10-25
voluntary announcement - completion of patient enrollment in a phase iii clinical trial of kn046 in combination with chemotherapy in the treatment of advanced unresectable or metastatic squamous nsclc 2021-10-15
monthly return of equity issuer on movements in securities for the month ended 30 september 2021 2021-10-08
voluntary announcement - updates on clinical data from phase ii clinical study of kn046 combined with chemotherapy in the first-line treatment of pdac for presentation at 2021 csco annual meeting 2021-09-17
voluntary announcement - research results on kn046 and kn026 for presentation at esmo congress 2021 2021-09-13
monthly return of equity issuer on movements in securities for the month ended 31 august 2021 2021-09-06
interim results announcement for the six months ended june 30, 2021 2021-08-27
list of directors and their role and function 2021-08-27